June 11, 2021
Janux Therapeutics, Inc., a biopharmaceutical company developing novel T cell engager immunotherapies, has announced the pricing of its initial public offering of 11,400,000 shares of its common stock at a price to the public of US$17 per share. The gross proceeds to Janux from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$193.8 million. All of the shares are being offered by Janux. In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 1,710,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.
Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by Bay Area partner Brian Cuneo and San Diego partner Matt Bush, with Bay Area associate Richard Kim and San Diego associates Julian Brody and Briana Goncalves. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with San Diego associate Kiera Murphy; on data privacy matters by Bay Area counsel Heather Deixler; on intellectual property matters by Bay Area partner Chris Hazuka, with San Diego associates Robert Yeh and Michael Sweeney; on benefits and compensation matters by Bay Area partner Ashley Wagner; and on tax matters by Bay Area partner Grace Lee, with Washington D.C. associate Eni Kassim.